MD An­der­son­'s Patrick Hwu to helm Mof­fitt Can­cer Cen­ter; Af­ter Rock­well Med­ical ouster, Robert Chioi­ni gets an­oth­er chance to lead

Patrick Hwu

→ The Mof­fitt Can­cer Cen­ter in Tam­pa has found its next pres­i­dent and CEO af­ter the im­broglio sur­round­ing the de­par­ture of Alan List.

Patrick Hwu, the head of can­cer med­i­cine at MD An­der­son Can­cer Cen­ter, has been tapped to lead Mof­fitt al­most ex­act­ly 8 months fol­low­ing the mass res­ig­na­tions of List, cen­ter di­rec­tor Thomas Sell­ers and 4 oth­er re­searchers for con­flict of in­ter­est re­gard­ing their work in Chi­na, one of sev­er­al high-pro­file ex­am­ples that in­clude Har­vard pro­fes­sor Charles Lieber.

Hwu, who of­fi­cial­ly starts Nov. 10, spent 17 of his 33 years in on­col­o­gy at MD An­der­son in promi­nent lead­er­ship po­si­tions. Be­sides his most re­cent role, he chaired the De­part­ment of Sar­co­ma Med­ical On­col­o­gy and was the first chair of the De­part­ment of Melanoma Med­ical On­col­o­gy. Hwu was al­so co-di­rec­tor of the Cen­ter for Can­cer Im­munol­o­gy Re­search.

“I’m con­fi­dent that our col­lec­tive ef­forts will fur­ther el­e­vate Mof­fitt’s lead­er­ship in can­cer pa­tient care, re­search and ed­u­ca­tion,” Hwu said in a state­ment.

Robert Chioi­ni

Robert Chioi­ni made head­lines back in 2018 when he at­tempt­ed to un­fire him­self as CEO of Rock­well Med­ical, as­sert­ing that those who vot­ed against him vi­o­lat­ed fed­er­al se­cu­ri­ties laws. With that messy dis­missal be­hind him fol­low­ing a set­tle­ment deal, Chioi­ni is back in the sad­dle, tak­ing over as CEO of Toron­to life sci­ences com­pa­ny SQI Di­ag­nos­tics. Er­ic Brouw­er has sub­se­quent­ly stepped aside as in­ter­im CEO, but he will con­tin­ue on as CSO at SQI.

“I look for­ward to work­ing with the team to un­lock the po­ten­tial across our suite of clin­i­cal and point of care di­ag­nos­tic prod­ucts,” Choi­ni, who found­ed Rock­well Med­ical in 1995, said in a state­ment. “Now more than ever, we see the im­por­tance of ac­cu­rate, wide­ly avail­able, and rapid di­ag­nos­tic tests.”

Ravi Rao

→ Start­ing Sept. 1, So­bi is bring­ing in Ravi Rao as head of R&D af­ter the EMA spurned the Stock­holm phar­ma’s pitch for ema­palum­ab (which has al­ready been ap­proved in the US) in late Ju­ly. Be­fore link­ing up with Stock­holm-based So­bi, which fo­cus­es on hema­tol­ogy and im­munol­o­gy, Rao wrapped up a run as CMO of Ae­glea Bio­ther­a­peu­tics. His Big Phar­ma ex­pe­ri­ence ranges from his 5 years at Roche, where he was group med­ical di­rec­tor, im­munol­o­gy clin­i­cal de­vel­op­ment, to 7 years as a VP at GSK, where he led the im­munol­o­gy and spe­cial­ty med­i­cine fran­chise up­on his de­par­ture to Ae­glea.

James Hussey has been around the block ei­ther as a pres­i­dent or CEO, and now he’s at the helm of Seneca Ther­a­peu­tics, look­ing to push its on­colyt­ic virus SVV-001 in­to clin­i­cal tri­als some­time in 2021. Hussey, who got his ca­reer go­ing at Bris­tol My­ers in the 1980s, has been the CEO of NeoPharm and NanoInk as well as the pres­i­dent of Sagent Phar­ma­ceu­ti­cals. Among his most re­cent roles, Hussey has been act­ing US pres­i­dent of Mor­phoSys and EVP of Athenex.

Kristof Ver­cruysse

Per­somed, a Bel­gian con­sor­tium look­ing to scale up de­vel­op­ment of per­son­al­ized can­cer vac­cines, has named Abl­ynx vet Kristof Ver­cruysse as their CEO. Most re­cent­ly he has been the chief de­vel­op­ment of­fi­cer and CMO at TargED Bio­phar­ma­ceu­ti­cals, for­mer­ly known as IO­VA. Ver­cruysse was di­rec­tor of clin­i­cal op­er­a­tions at Abl­ynx from 2007-13.

Matt Brokaw has been cho­sen to take the helm as pres­i­dent and CEO of med­ical de­vice com­pa­ny Aerin Med­ical, which aims to pro­vide non-in­va­sive pro­ce­dures for treat­ing chron­ic nasal air­way con­di­tions. Brokaw has pre­vi­ous­ly held lead­er­ship po­si­tions in mar­ket­ing at com­pa­nies with ENT port­fo­lios, such as Smith+Nephew (which just ac­quired Tusker Med­ical in Jan­u­ary) and Stryk­er. Along with Brokaw’s ap­point­ment, Aerin Med­ical al­so re­vealed the close of their $48 mil­lion eq­ui­ty fi­nanc­ing.

→ Fo­cused on the re­peatome in drug de­vel­op­ment, ROME Ther­a­peu­tics has brought on Den­nis Za­ller to be their CSO. A for­mer ex­ec­u­tive di­rec­tor at Mer­ck and Cel­gene/BMS, Za­ller has col­lab­o­rat­ed in the past with ROME’s pres­i­dent, CEO and co-founder, Rosana Kapeller. On Wednes­day our Max Gel­man spoke with Za­ller and Kapeller, which you can read here.

→ Long­time phar­ma ex­ec Paul Ko­rner is head­ed to Prince­ton, NJ women’s health­care com­pa­ny Ag­ile Ther­a­peu­tics as their CMO. Ko­rner has held a va­ri­ety of ex­ec­u­tive ti­tles, in­clud­ing SVP of US de­vel­op­ment at Fer­ring Phar­ma­ceu­ti­cals, which has made women’s health one of its ar­eas of fo­cus. He just com­plet­ed a more than year-and-a-half run as Ax­o­vant’s SVP, clin­i­cal de­vel­op­ment & med­ical af­fairs, and from 2005-08, Ko­rner was Bay­er’s VP of med­ical af­fairs, women’s health.

Al­ka Chaubey

Al­ka Chaubey has made her way to San Diego-based gene se­quenc­ing play­er Bio­nano Ge­nomics as their first CMO. A well-known fig­ure through­out the mol­e­c­u­lar di­ag­nos­tics and cy­to­ge­net­ics com­mu­ni­ties, Chaubey is cur­rent­ly the head of cy­toge­nomics for PerkinElmer Ge­nomics, and she al­so spent 10 years at South Car­oli­na’s Green­wood Ge­net­ic Cen­ter, in­clud­ing 7 years as their di­rec­tor.

→ Bio­mark­er-dri­ven Ike­na On­col­o­gy has turned to Big Phar­ma vet Ser­gio San­til­lana to be their CMO. San­til­lana al­so led med­ical op­er­a­tions at Mer­ri­mack Phar­ma­ceu­ti­cals and ARI­AD Phar­ma­ceu­ti­cals pri­or to join­ing Boston-based Ike­na. He’s al­so held a num­ber of on­col­o­gy clin­i­cal de­vel­op­ment lead­er­ship roles at Eli Lil­ly (2002-06), GSK (2006-14) and Take­da (2014-16), where he was their se­nior med­ical di­rec­tor, on­col­o­gy clin­i­cal re­search.

Yasir Al-Wa­keel

Nor­bert Bischof­berg­er has been busy all sum­mer bol­ster­ing his ex­ec­u­tive lead­er­ship at Kro­nos Bio, and this week is no dif­fer­ent as Yasir Al-Wa­keel heads to the biotech as their CFO and head of cor­po­rate de­vel­op­ment af­ter a 3-year run as CFO and head of strat­e­gy at Neon Ther­a­peu­tics. Al-Wa­keel held the same ti­tles at Mer­ri­mack Phar­ma­ceu­ti­cals as he does now at Kro­nos, which gob­bled up two of Gilead’s SYK in­hibitors in Ju­ly. We fea­tured him in our 2018 re­port on the un­der-40 crowd mak­ing a mark in biotech.

→ San Diego im­munother­a­py play­er Fate Ther­a­peu­tics has en­list­ed Cel­gene vet Ed­ward Du­lac as their new CFO. Du­lac start­ed at Cel­gene in 2012 as their di­rec­tor of glob­al mar­ket­ing and rose to VP, busi­ness de­vel­op­ment and strat­e­gy be­fore jump­ing over to Fate, which de­vel­ops off-the-shelf cell prod­ucts with its pro­pri­etary in­duced pluripo­tent stem cell (iP­SC) prod­uct plat­form.

→ British Co­lum­bia-based Xenon Phar­ma­ceu­ti­cals, tar­get­ing neu­ro­log­i­cal dis­or­ders, has tapped Chris Von Seg­gern as chief com­mer­cial of­fi­cer. Dur­ing a tenure of near­ly 12 years at ClearView Health­care Part­ners, most of Von Seg­gern’s en­er­gy was geared to­ward or­phan dis­eases and trans­for­ma­tion­al tech­nolo­gies.

Richard Katz has an­nounced his res­ig­na­tion as CFO at Liq­uidia Tech­nolo­gies, which is look­ing to go toe-to-toe with stan­dard-of-care Ty­va­so in the de­vel­op­ment of their drug LIQ861 for pul­monary ar­te­r­i­al hy­per­ten­sion. Steven Bariahtaris is step­ping in as in­ter­im CFO at the Re­search Tri­an­gle phar­ma un­til the po­si­tion is filled. Bariahtaris was a long­time J&J ex­ec in sev­er­al ca­pac­i­ties, leav­ing the phar­ma gi­ant ear­ly this year as their chief au­dit ex­ec­u­tive. While at J&J, he was al­so their CFO & VP of fi­nance for Janssen Amer­i­c­as.

Ju­lianne Aver­ill

Ju­lianne Aver­ill has tak­en on the CFO post at Bay Area in­fec­tious dis­ease di­ag­nos­tic tech start­up Alveo Tech­nolo­gies, which an­nounced a col­lab­o­ra­tion with Janssen Phar­ma­ceu­ti­cals in April to bring its be.well test­ing sys­tem to mar­ket. A De­loitte vet, Aver­ill hails from Black­Thorn Ther­a­peu­tics, where she was their VP, fi­nance since Jan­u­ary 2019.

→ Rare dis­ease biotech San­i­fit — which raised near­ly $81 mil­lion last June in Spain’s largest-ever pri­vate biotech fundraise — has made the ad­di­tion of Adam Levy as CFO. Most re­cent­ly, Levy served as CBO of Brick­ell Biotech and has pre­vi­ous ex­pe­ri­ence with mi­Ra­gen Ther­a­peu­tics, Mer­rill Lynch and Jef­feries Group among oth­ers.

→ San Diego-based biotech Zai Lab has snapped up Ty Ed­mond­son as chief le­gal of­fi­cer. Ed­mond­son hails from Bio­gen, where he served as SVP, chief cor­po­ra­tion coun­sel and as­sis­tant sec­re­tary. Pri­or to Bio­gen, Ed­mond­son served in roles at Sepra­cor, Sum­it­o­mo Dainip­pon Phar­ma, Ei­sai and Bris­tol My­ers Squibb among oth­ers.

Liz Hen­der­son

Mer­ck KGaA has made Liz Hen­der­son re­gion­al VP of Mer­ck Bio­phar­ma Asia Pa­cif­ic (APAC), based in Sin­ga­pore. A Pfiz­er and Am­gen vet, Hen­der­son has spent the last 18 months in Lon­don as Mer­ck’s man­ag­ing di­rec­tor and GM, Mer­ck UK & Re­pub­lic of Ire­land and has been at Mer­ck since 2009. In her new role, she will cov­er 11 APAC coun­tries across the phar­ma’s 4 ther­a­py ar­eas: on­col­o­gy, fer­til­i­ty, neu­rol­o­gy and im­munol­o­gy, and gen­er­al med­i­cine and en­docrinol­o­gy.

Tyme Tech­nolo­gies — fo­cused on the de­vel­op­ment of can­cer me­tab­o­lism-based ther­a­pies — has named John Roth­man as EVP, prod­uct de­vel­op­ment. Roth­man pre­vi­ous­ly served in roles at Scher­ing-Plough, Roche and Ad­vax­is.

Lori Hoff­man has moved to Prince­ton, NJ-based Slay­back Phar­ma as their head of al­liance man­age­ment af­ter lead­ing Fron­ti­da’s al­liance man­age­ment func­tion the last 3 years. Be­fore Fron­ti­da, Hoff­man spent more than 9 years at Sagent Phar­ma­ceu­ti­cals, the ma­jor­i­ty of which was spent as their se­nior di­rec­tor, busi­ness de­vel­op­ment.

Ted Love

Seat­tle Ge­net­ics has reeled in Glob­al Blood Ther­a­peu­tics pres­i­dent and CEO Ted Love to its board of di­rec­tors. Love brings a wealth of ex­pe­ri­ence from Onyx Phar­ma­ceu­ti­cals, Nu­velo, Ther­a­vance and Genen­tech.

Be­yond­Spring is mak­ing a big splash with the ad­di­tion of Ravin­dra Ma­jeti to its board of di­rec­tors. Ma­jeti co-found­ed Forty Sev­en out of Stan­ford in 2016, be­fore the com­pa­ny was ac­quired by Gilead in a $4.9 bil­lion buy­out. Af­ter snag­ging $123 mil­lion from the deal, Ma­jeti cur­rent­ly serves as chief, di­vi­sion of hema­tol­ogy at Stan­ford Uni­ver­si­ty.

Gar­ry Men­zel

TCR² Ther­a­peu­tics CEO Gar­ry Men­zel has been giv­en a seat on ge­net­ic dis­ease biotech Stoke Ther­a­peu­tics’ board of di­rec­tors. Men­zel is al­so a found­ing di­rec­tor at Black Di­a­mond Ther­a­peu­tics.

Michael Cham­bers has been se­lect­ed to the board of di­rec­tors at Calviri, a can­cer-fo­cused spin­out of the Biode­sign In­sti­tute at Ari­zona State. Cham­bers left his CEO post at Alde­vron but re­mains their chair­man.

Liz Kwo

Flex­ion Ther­a­peu­tics, which struck a deal in April to de­vel­op and com­mer­cial­ize Zil­ret­ta in Chi­na, has brought on Liz Kwo as a mem­ber of their board of di­rec­tors. Kwo is the staff VP, clin­i­cal da­ta an­a­lyt­ics at An­them.

Jakob Dupont, for­mer CMO at Gos­samer Bio, has joined Apex­i­gen‘s board of di­rec­tors. Dupont cur­rent­ly serves as EVP, head of glob­al re­search and de­vel­op­ment at Atara Bio­ther­a­peu­tics and was pre­vi­ous­ly at Genen­tech/Roche and On­coMed Phar­ma­ceu­ti­cals.

At the In­flec­tion Point for the Next Gen­er­a­tion of Can­cer Im­munother­a­py

While oncology researchers have long pursued the potential of cellular immunotherapies for the treatment of cancer, it was unclear whether these therapies would ever reach patients due to the complexity of manufacturing and costs of development. Fortunately, the recent successful development and regulatory approval of chimeric antigen receptor-engineered T (CAR-T) cells have demonstrated the significant benefit of these therapies to patients.

All about Omi­cron; We need more Covid an­tivi­rals; GSK snags Pfiz­er’s vac­cine ex­ec; Janet Wood­cock’s fu­ture at FDA; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

The slate of products we’re offering here at Endpoints is continuing to grow, and it’s not just limited to editorial. If you haven’t, do visit your reader profile to see if there are any other weekly newsletters you’re interested in — as each comes with its own exclusive content. And don’t miss the publisher’s note from Arsalan Arif on Endpoints Studio, our latest avenue for advertising on Endpoints.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Usama Malik

Ex-Im­munomedics CFO charged with in­sid­er trad­ing, faces up to 20 years in prison af­ter al­leged­ly tip­ping off girl­friend and rel­a­tives of a PhI­II suc­cess

The former CFO of Immunomedics, who helped steer the company to its $21 billion buyout by Gilead last year, has been charged with insider trading, the Department of Justice announced Thursday.

Usama Malik tipped off his then-girlfriend and four others that a Phase III study for Trodelvy would be stopped early four days before Immunomedics publicly announced the result in April 2020, DoJ alleged in its complaint. The individuals then purchased Immunomedics shares, selling them after the news broke and Immunomedics’ stock price doubled.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Merck's new antiviral molnupiravir (Quality Stock Arts / Shutterstock)

As Omi­cron spread looms, oral an­tivi­rals ap­pear to be one of the best de­fens­es — now we just need more

After South African scientists reported a new Covid-19 variant — dubbed Omicron by the WHO — scientists became concerned about how effective vaccines and monoclonal antibodies might be against it, which has more than 30 mutations in the spike protein.

“I think it is super worrisome,” Dartmouth professor and Adagio co-founder and CEO Tillman Gerngross told Endpoints News this weekend. Moderna CEO Stéphane Bancel echoed similar concerns, telling the Financial Times that experts warned him, “This is not going to be good.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

In­cor­po­rat­ing Ex­ter­nal Da­ta in­to Clin­i­cal Tri­als: Com­par­ing Dig­i­tal Twins to Ex­ter­nal Con­trol Arms

Most drug development professionals are familiar with the nerve-racking wait for the read-out of a large trial. If it’s negative, is the investigational therapy ineffective? Or could the failure result from an unforeseen flaw in the design or execution of the protocol, rather than a lack of efficacy? The team could spend weeks analyzing data, but a definitive answer may be elusive due to insufficient power for such analyses in the already completed trial. These problems are only made worse if the trial had lower enrollment, or higher dropout than expected due to an unanticipated event like COVID-19. And if a trial is negative, the next one is likely to be larger and more costly — if it happens at all.

Ab­b­Vie tacks on a new warn­ing to Rin­voq la­bel as safe­ty frets crimp JAK class

The safety problems that continue to plague the JAK class as new data highlight some severe side effects are casting a large shadow over AbbVie’s Rinvoq.

As a result of a recent readout highlighting major adverse cardiac events (MACE), malignancy, mortality and thrombosis with Xeljanz a couple of months ago, AbbVie put out a notice late Friday afternoon that it is adding the new class risks to its label for their rival drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Biospec­i­men M&A: Dis­cov­ery ac­quires Al­bert Li's he­pa­to­cyte project; PhI­II tri­al on Bay­er's Nube­qa reached pri­ma­ry end­point

Discovery Life Sciences has acquired what claims to be the Maryland-based host of the world’s largest hepatocyte inventory, known as IVAL, to help researchers select more effective and safer drug candidates in the future.

The combined companies will now serve a wider range of drug research and development scientists, according to Albert Li, who founded IVAL in 2004 and is set to join the Discovery leadership team as the CSO of pharmacology and toxicology.

Pfiz­er, Am­gen and Janssen seek fur­ther clar­i­ty on FDA's new ben­e­fit-risk guid­ance

Three top biopharma companies are seeking more details from the FDA on how the agency conducts its benefit-risk assessments for new drugs and biologics.

While Pfizer, Amgen and Janssen praised the agency for further spelling out its thinking on the subject in a new draft guidance, including a discussion of patient experience data as part of the assessment, the companies said the FDA could’ve included more specifics in the 20-page draft document.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Re­searchers move clos­er to de­ci­pher­ing blood clots from As­traZeneca, J&J's Covid-19 vac­cines

Researchers may be nearing an answer for the mysterious and life-threatening blood clots that appeared on very rare occasions in people who received the J&J or AstraZeneca Covid-19 vaccine.

The new work builds on an early hypothesis researchers in Norway put forward last spring, when the cases first cropped up. They proposed the events were similar to blood clots that can occur in a small subset of patients who receive heparin, one of the most commonly used blood thinners.